BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Delpacibart etedesiran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Delpacibart etedesiran\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07008469-11253@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Delpacibart etedesiran: Phase 3 readout est. (NCT07008469)
DESCRIPTION:Delpacibart etedesiran\, phase 3\, Myotonic Dystrophy Type 1.\n
 Study: Global Open-Label Extension Study of Del-desiran for the Treatment 
 of DM1\nEstimated primary completion: October 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/delpacibart-etedesiran#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07008469
URL:https://assetmemo.bio/drug/delpacibart-etedesiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
